Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Non-Current Liabilities: 2015-2018

Historic Total Non-Current Liabilities for Assembly Biosciences (ASMB) over the last 4 years, with Dec 2018 value amounting to $38.9 million.

  • Assembly Biosciences' Total Non-Current Liabilities fell 8.84% to $38.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $38.9 million, marking a year-over-year decrease of 8.84%. This contributed to the annual value of $38.9 million for FY2018, which is 8.84% down from last year.
  • Per Assembly Biosciences' latest filing, its Total Non-Current Liabilities stood at $38.9 million for Q4 2018, which was down 0.04% from $38.9 million recorded in Q3 2018.
  • Assembly Biosciences' Total Non-Current Liabilities' 5-year high stood at $55.4 million during Q1 2017, with a 5-year trough of $11.1 million in Q4 2016.
  • For the 3-year period, Assembly Biosciences' Total Non-Current Liabilities averaged around $34.2 million, with its median value being $39.6 million (2018).
  • In the last 5 years, Assembly Biosciences' Total Non-Current Liabilities skyrocketed by 377.93% in 2017 and then fell by 26.49% in 2018.
  • Assembly Biosciences' Total Non-Current Liabilities (Quarterly) stood at $11.6 million in 2015, then fell by 4.14% to $11.1 million in 2016, then surged by 283.93% to $42.7 million in 2017, then decreased by 8.84% to $38.9 million in 2018.
  • Its Total Non-Current Liabilities stands at $38.9 million for Q4 2018, versus $38.9 million for Q3 2018 and $40.2 million for Q2 2018.